Crysvita 30mg (Burosumab-Twza Vials) 30mg/ml x 1ml

Crysvita 30mg (burosumab-twza) is a prescription medication supplied in vials for subcutaneous injection. It is used to treat specific bone disorders by regulating phosphate levels. Store at 2-8°C to maintain potency. Always follow healthcare provider guidance.

Strength

30mg/ml x 1ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Kyowa Kirin

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Crysvita 30mg is used to address conditions related to low phosphate levels in the body, such as X-linked hypophosphatemia (XLH). It helps manage symptoms by supporting bone health and mineralization. This medication is designed for long-term use under medical supervision. People often ask, 'what is Crysvita 30mg used for' to understand its role in treatment.

Side Effects

Crysvita 30mg works by targeting the underlying cause of phosphate imbalance, which may improve bone strength and reduce discomfort over time. Users may notice gradual improvements in mobility and energy levels. Individual responses vary, and consistent use is important for best results.

Precautions & Warnings

Keep Crysvita 30mg refrigerated between 2-8°C and protect it from light. Do not freeze or shake the vials. Always check the expiration date before use. Discard any unused medication as directed by your pharmacist to ensure safety.

Avoid Interactions

Crysvita 30mg may interact with other medications that affect phosphate levels or bone metabolism. Avoid combining it with high-dose vitamin D supplements unless advised by a doctor. Inform your healthcare provider about all current medications to prevent potential interactions.

Frequently Asked Questions

Store Crysvita 30mg vials in the refrigerator at 2-8°C and protect them from light. Do not freeze or shake the vials.

Crysvita 30mg is used to treat conditions like X-linked hypophosphatemia (XLH) by helping regulate phosphate levels in the body.

The safety of Crysvita 30mg during pregnancy has not been established. Consult a healthcare provider for personalized advice.

The dosing schedule for Crysvita 30mg is determined by a healthcare professional based on individual needs.

Some users may experience injection site reactions or mild discomfort. Report any persistent issues to a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.